An early-stage **Moderna** or **BioNTech**, but applying nanotechnology instead of mRNA to develop treatments for neurological conditions like ALS and MS.

A nanotechnology-driven, clinical-stage **Biogen** (known for neurology) targeting diseases like ALS.

• CNM-Au8: A lead clean-surfaced nanotechnology (CSN) therapeutic drug currently in various clinical trials for neurological diseases such as ALS, Multiple Sclerosis, and Parkinson's Disease.
• CNM-AgZn17: A gel polymer suspension of silver and zinc ions being developed for the treatment of infectious diseases and to accelerate wound healing.
• CNM-ZnAg: A broad-spectrum antiviral and antibacterial agent designed to treat infectious diseases like COVID-19 and provide immune support.
• CNM-PtAu7: A gold-platinum clean-surfaced nanotechnology (CSN) therapeutic intended for oncology applications.
• rMetx: An aqueous zinc-silver ion dietary supplement marketed and distributed by the company.
• KHC46: An aqueous gold dietary supplement consisting of very low-concentration gold nanoparticles.

• Patients with Neurological Disorders: This category includes individuals diagnosed with conditions such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's Disease. Clene's lead drug, CNM-Au8, is specifically being developed for these patient populations.
• Patients with Infectious Diseases and Wound Healing Needs: This category encompasses individuals suffering from various infectious diseases and those requiring solutions for accelerated wound healing. Clene is developing CNM-AgZn17 and CNM-ZnAg for these therapeutic areas, as well as for general immune support.
• Health-Conscious Consumers: This category primarily relates to Clene's dietary supplements, rMetx and KHC46. These products are marketed to individuals seeking general immune support, detoxification, or other health benefits from zinc-silver and gold nanoparticles.

Rob Etherington, President, Chief Executive Officer, and Director

Mr. Etherington was appointed CEO of Clene in April 2013 and brings over 30 years of sales, marketing, and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, where he led U.S. commercial operations. He was the first U.S. commercial employee at Actelion, which went public in 2000 and was later acquired by Johnson & Johnson in 2017. He also held various sales and marketing roles at Parke-Davis, a division of Pfizer, culminating in a Team Leader position overseeing the drug Lipitor. As the founding CEO of Clene, he has raised over $150 million in equity financings.

Morgan R. Brown, Chief Financial Officer and Principal Accounting Officer

Mr. Brown has more than 30 years of finance and accounting experience, with 23 years spent in biotech, pharmaceutical, and medical device companies. He has served in similar financial leadership roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research, and NPS Pharmaceuticals Inc. Earlier in his career, he worked at the accounting firm KPMG. Mr. Brown is a Certified Public Accountant (CPA).

Mark Mortenson, Chief Science Officer

Mr. Mortenson is a co-inventor of the proprietary technology platform that Clene utilizes to produce its novel clean-surfaced nanotechnology (CSN) therapeutics.

Benjamin Greenberg, MD, MHS, FAAN, Head of Medical, Neurology

Dr. Greenberg joined Clene's executive team around March 2023. He is an internationally recognized expert in treating central nervous system disorders and brings extensive clinical and research experience to the company, particularly in multiple sclerosis (MS) and other rare neurological disorders. He also holds positions as a professor of neurology and Vice Chair of Clinical and Translational Research in the Department of Neurology at UT Southwestern Medical Center.

Michael Hotchkin, Senior Vice President of Product Development

Mr. Hotchkin is a member of Clene's executive team.

The key risks for Clene Inc. (CLNN) primarily stem from its nature as a clinical-stage pharmaceutical company developing novel therapeutics for complex neurodegenerative diseases.

1. Clinical Trial and Regulatory Approval Risk: Clene's business success is overwhelmingly dependent on the ability of its lead drug candidate, CNM-Au8, and other pipeline products to successfully complete ongoing and planned clinical trials and subsequently obtain regulatory approval from health authorities like the FDA. The company has faced prior instances where the FDA deemed trial data insufficient for accelerated approval of its ALS drug. Delays and uncertainties in the regulatory pathway for CNM-Au8 in ALS, including extended timelines for New Drug Application (NDA) submission, highlight this significant hurdle. Negative trial results, safety concerns, or regulatory setbacks could lead to a substantial devaluation of the company.
2. Funding and Capital Risk (Going Concern): As a clinical-stage biopharmaceutical company, Clene incurs significant research and development expenses without substantial commercial revenue from its primary drug candidates. The company has reported ongoing losses, negative net margins, and high cash burn. Clene has acknowledged "substantial doubt about its ability to continue as a going concern without additional funding". While the company has engaged in financing activities, including registered direct offerings and debt facilities, these often lead to share dilution for existing shareholders and may not guarantee long-term operational runway. Furthermore, Clene has faced notices regarding its market value falling below Nasdaq requirements, posing a risk of delisting if financial health does not improve.
3. Competition and Market Acceptance: Even if Clene's drug candidates receive regulatory approval, they will enter highly competitive markets for serious neurodegenerative diseases such as ALS, multiple sclerosis, and Parkinson's disease. The company's novel clean-surfaced nanotechnology (CSN) therapeutics will need to demonstrate clear superiority or significant differentiation over existing treatments and other therapies in development to gain substantial market share and acceptance among physicians and patients.

CNM-Au8

• Amyotrophic Lateral Sclerosis (ALS) Treatments: The global market size for ALS treatments was estimated at USD 667.3 million in 2023 and is projected to reach USD 987.6 million by 2030, growing at a CAGR of 5.8% from 2024 to 2030. The North American market held a revenue share of 37.7% in 2023. The U.S. market is expected to reach USD 515.6 million by the end of 2032.
• Multiple Sclerosis (MS) Treatments: The global multiple sclerosis drugs market size was estimated to be USD 21.26 billion in 2024 and is predicted to increase to approximately USD 45.90 billion by 2034, expanding at a CAGR of 8.00%. The global multiple sclerosis therapeutic market size was valued at USD 29.51 billion in 2025 and is anticipated to reach around USD 52.32 billion by 2035, growing at a CAGR of 5.89%. The Multiple Sclerosis market size in the U.S. was approximately USD 16,000 million in 2024. The U.S. multiple sclerosis therapeutic market size is expected to be worth around USD 13.48 billion by 2035 from USD 7.42 billion in 2025, with a CAGR of 6.15%.
• Parkinson's Disease (PD) Treatments: The global Parkinson's disease treatment market size was estimated at USD 5.65 billion in 2024 and is expected to reach USD 7.58 billion by 2030, growing at a CAGR of 5.04% from 2025 to 2030. The global Parkinson's Disease Treatment Market was valued at USD 5.37 billion in 2023 and is projected to reach USD 8.75 billion by 2032, reflecting a CAGR of 5.57%. The U.S. Parkinson's disease drugs market holds a prominent share.
• Chronic Optic Neuropathy Treatments: The 7 major optic neuropathy market reached a value of USD 3.1 billion in 2024 and is expected to reach USD 4.6 billion by 2035, exhibiting a CAGR of 3.57% during 2025-2035. The global Optic Neuropathy Treatment market size is predicted to grow from US$ 4,594 million in 2025 to US$ 6,222 million in 2031, at a CAGR of 5.2%. North America is the largest market for optic nerve disorders treatment, holding approximately 45% of the global market share. The optic neuropathy management industry will be valued at USD 4.74 billion by 2025 and is projected to reach USD 7.72 billion by 2035, growing at a CAGR of 5.0%.

CNM-AgZn17

• Infectious Disease Treatments: The global infectious disease therapeutics market size was estimated at USD 136.2 billion in 2024 and is expected to grow from USD 139.6 billion in 2025 to USD 190.1 billion in 2034, at a CAGR of 3.5%. Another estimate places the global infectious disease therapeutics market size at USD 243,409.1 million in 2024, projected to reach USD 283,908.2 million by 2030, growing at a CAGR of 3.5%. The global infectious disease treatments market is expected to grow from $72.5 billion in 2025 to $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9%.
• Wound Healing: The global wound healing market size was valued at USD 19.55 billion in 2024 and is expected to reach USD 26.85 billion by 2032, at a CAGR of 4.05%. The global wound care market size was estimated at USD 24.9 billion in 2024 and is expected to grow from USD 26.3 billion in 2025 to USD 44.2 billion by 2034 at a CAGR of 5.9%. The U.S. wound care market size is expected to hit around USD 13.09 billion by 2034, growing at a CAGR of 5%.

CNM-ZnAg

• Broad-Spectrum Antiviral and Antibacterial Agents:
  • Antiviral Agents: The global antiviral drugs market size was estimated at USD 62.85 billion in 2025 and is predicted to increase to approximately USD 89.86 billion by 2035, expanding at a CAGR of 3.64%. The antiviral segment dominated the anti-infective agents market with a 50.9% share in 2024.
  • Antibacterial Agents: The global antimicrobials market is projected to expand from USD 117.6 billion in 2026 to USD 197.0 billion by 2036, registering a CAGR of 5.3%. Antibacterial agents are expected to dominate global demand in the antimicrobials market with a 45.3% share. The antibiotics segment dominated the infectious disease therapeutics market in 2024 and was valued at USD 48.3 billion. The global antimicrobial agent market size was valued at USD 3.66 billion in 2024 and is expected to reach USD 7.29 billion by 2032, at a CAGR of 9.00%.

CNM-PtAu7

• Oncology Applications: The global oncology market size was estimated at USD 320.3 billion in 2024 and is expected to grow from USD 345.1 billion in 2025 to USD 866.1 billion by 2034, at a CAGR of 10.8%. The global oncology market size was estimated at USD 249.53 billion in 2024 and is poised to grow to USD 648.73 billion by 2033, growing at a CAGR of 11.2%. The U.S. oncology market size was valued at USD 89.39 billion in 2025 and is anticipated to reach around USD 177.67 billion by 2035, growing at a CAGR of 6.44%. The U.S. oncology market size was estimated at USD 72.74 billion in 2024 and is predicted to be worth around USD 220.21 billion by 2034, at a CAGR of 11.71%.

For Clene Inc. (CLNN), the expected drivers of future revenue growth over the next 2-3 years are primarily centered around the clinical development and potential commercialization of its lead drug candidate, CNM-Au8, across multiple neurodegenerative diseases, and the advancement of its broader nanotechnology therapeutics pipeline.

1. Commercialization of CNM-Au8 for Amyotrophic Lateral Sclerosis (ALS): The most significant anticipated driver of revenue growth is the potential regulatory approval and subsequent commercial launch of CNM-Au8 for the treatment of ALS. Clene anticipates submitting a New Drug Application (NDA) for CNM-Au8 under an accelerated approval pathway by the end of June 2026. Following a potential FDA acceptance and the issuance of a Prescription Drug User Fee Act (PDUFA) date in the second half of 2026, there is a prospect for commercial launch as early as 2027. Analysts forecast a substantial increase in Clene's revenue for 2027 and 2028, largely attributable to the market entry of CNM-Au8 for ALS.

2. Expansion of CNM-Au8 into Multiple Sclerosis (MS) and Parkinson's Disease (PD) Markets: Beyond ALS, Clene is actively developing CNM-Au8 for other neurodegenerative conditions, viewing it as a "pipeline in a product." The company plans to finalize its Phase 3 clinical trial design for MS, focusing on cognition as an endpoint, after incorporating FDA feedback. Continued progression in these clinical trials and eventual regulatory submissions for MS and PD would open up significant new markets for CNM-Au8, expanding its revenue-generating potential in the medium term.

3. Development and Potential Commercialization of Other Nanotechnology Therapeutics: Clene's broader pipeline of clean-surfaced nanotechnology (CSN) therapeutics, including CNM-AgZn17 for infectious diseases and wound healing, CNM-ZnAg as an antiviral and antibacterial agent, and CNM-PtAu7 for oncology applications, represents additional future revenue growth opportunities. While specific commercialization timelines for these assets within the next 2-3 years are less defined than for CNM-Au8, their continued development, successful clinical progression, and potential for future partnerships or market entry could contribute to longer-term revenue expansion.

Share Issuance

• In January 2026, Clene announced a registered direct offering that raised over $28 million.
• An initial tranche of this offering generated approximately $6.03 million from the sale of 928,333 common shares and accompanying warrants at $6.50 per unit.
• Two additional financing tranches, totaling over $22 million, are contingent upon the New Drug Application (NDA) acceptance and FDA approval for CNM-Au8 in ALS.

Inbound Investments

• The January 2026 registered direct offering was oversubscribed and included investments from new, existing, and insider investors, with Boxer Capital, Coastlands Capital, and Vivo Capital identified as lead investors.
• The initial tranche of this financing is expected to provide Clene with an operating runway into the third quarter of 2026.
• The completion of the full $28 million financing, including contingent tranches, is projected to provide sufficient capital for the company into early 2027.

Capital Expenditures

• For the year ended December 31, 2025, Clene reported capital expenditures of $15,000.
• The company's financial focus appears to be on research and development, with expenses of $14.0 million in 2025 and $20.1 million in 2024, indicating a priority on clinical trials and drug development over significant investments in physical assets.